ArticleCancers2022
Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Delta radiomics: an updated systematic review.La Radiologia medica · 2024Pooled it
- Article
- Preoperative CT Radiomics for Assessing Pathological Response to Neoadjuvant Chemoimmunotherapy in Locally Advanced Non-Small-Cell Lung Cancer.Journal of clinical medicine · 2026Article
- Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer.Journal of inflammation research · 2026Review
- CT-based delta-radiomics signature of visceral adipose tissue for prediction of disease progression in ileal stricturing Crohn's disease.Japanese journal of radiology · 2025Article
- Article
- The first case of esophageal mediastinal fistula after immunotherapy for non-small cell lung cancer: case report and literature review.Journal of cardiothoracic surgery · 2025Review
- Imaging patterns and recommendations for diagnosis, staging, and management of lung cancer.BJR open · 2025Review
- A study on the prediction of targeted therapy efficacy in advanced lung adenocarcinoma patients with EGFR mutations using CT-based delta-radiomics model.Frontiers in medicine · 2025Article
- Article
- Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC.Scientific reports · 2024Article
- [Advancements in Radiomics for Immunotherapy of Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Prediction of Ablation Rate for High-Intensity Focused Ultrasound Therapy of Adenomyosis in MR Images Based on Multi-model Fusion.Journal of imaging informatics in medicine · 2024Article
- [Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients.Clinical and experimental medicine · 2024Review
- Article
- Rethinking the potential role of dose painting in personalized ultra-fractionated stereotactic adaptive radiotherapy.Frontiers in oncology · 2024Article
- Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer.Frontiers in immunology · 2024Review
- Combining Low-Dose Computer-Tomography-Based Radiomics and Serum Metabolomics for Diagnosis of Malignant Nodules in Participants of Lung Cancer Screening Studies.Biomolecules · 2023Article
- Delta-radiomics in cancer immunotherapy response prediction: A systematic review.European journal of radiology open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Delta-radiomics is a branch of radiomics in which features are confronted after time or after introducing an external factor (such as treatment with chemotherapy or radiotherapy) to extrapolate prognostic data or to monitor a certain condition. Immune checkpoint inhibitors (ICIs) are currently revolutionizing the treatment of non-small cell lung cancer (NSCLC); however, there are still many issues in defining the response to therapy. Contrast-enhanced CT scans of 33 NSCLC patients treated with ICIs were analyzed; altogether, 43 lung lesions were considered. The radiomic features of the lung lesions were extracted from CT scans at baseline and at first reassessment, and their variation (delta, Δ) was calculated by means of the absolute difference and relative reduction. This variation was related to the final response of each lesion to evaluate the predictive ability of the variation itself. Twenty-seven delta features have been identified that are able to discriminate radiologic response to ICIs with statistically significant accuracy. Furthermore, the variation of nine features significantly correlates with pseudo-progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.